Bridge Biotherapeutics Signs a License Agreement with Konkuk University for its Back-Eye Disease Therapy
Shots:
- Konkuk University to receive $0.25M upfront- ~$8.1M development and commercial milestones while Bridge Biotherapeutics to get WW exclusive license for the compound and will lead preclinical and development process of the therapy
- Additionally- in 2019- Bridge Biotherapeutics signed a license agreement with Boehringer Ingelheim to develop BBT-877- an autotaxin inhibitor targeting fibrosing interstitial lung diseases including IPF
- Bridge Biotherapeutics’ pipeline includes BBT-401- being evaluated in P-II study for UC and BBT-176- a potent targeted cancer therapy for NSCLC
Click here to read full press release/ article | Ref: PRNewswire | Image: Bridge Biotherapeutics
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
